

DOI: 10.1038/s41467-018-02947-0

OPEN

Author Correction: Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia Xi Jiang^{1,2,3}, Chao Hu^{1,2,4}, Kyle Ferchen¹, Ji Nie⁵, Xiaolong Cui⁵, Chih-Hong Chen⁶, Liting Cheng⁷,

Xi Jiang^{1,2,3}, Chao Hu^{1,2,4}, Kyle Ferchen¹, Ji Nie⁵, Xiaolong Cui⁵, Chih-Hong Chen⁶, Liting Cheng⁷, Zhixiang Zuo^{1,8}, William Seibel⁹, Chunjiang He¹⁰, Yixuan Tang⁷, Jennifer R. Skibbe¹, Mark Wunderlich¹¹, William C. Reinhold¹², Lei Dong^{1,3}, Chao Shen^{1,3}, Stephen Arnovitz², Bryan Ulrich², Jiuwei Lu¹, Hengyou Weng^{1,2,3}, Rui Su^{1,3}, Huilin Huang^{1,3}, Yungui Wang^{1,2,4}, Chenying Li^{1,3,4}, Xi Qin^{1,3}, James C. Mulloy¹¹, Yi Zheng¹¹, Jiajie Diao ¹, Jie Jin⁴, Chong Li⁷, Paul P. Liu¹³, Chuan He⁵, Yuan Chen⁶ & Jianjun Chen^{1,2,3}

Correction to: Nature Communications https://doi.org/10.1038/s41467-017-02290-w; published online: 13 Dec 2017

The original version of this Article contained an error in the spelling of the author James C. Mulloy, which was incorrectly given as James Mulloy. This has now been corrected in both the PDF and HTML versions of the Article.

Published online: 09 February 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018

1

¹Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219, USA. ² Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA. ³ Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA. ⁴ Department of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang 310003, China. ⁵ Department of Chemistry, Department of Biochemistry and Molecular Biology, Institute for Biophysical Dynamics, Howard Hughes Medical Institute, University of Chicago, Chicago, IL 60637, USA. ⁶ Department of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA. ⁷ Key Laboratory of Luminescence and Real-time Analytical Chemistry (Ministry of Education), College of Pharmaceutical Sciences, Southwest University, Chongqing 400715, China. ⁸ Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China. ⁹ Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA. ¹⁰ School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China. ¹¹ Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA. ¹² Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA. ¹³ Genetics and Molecular Biology Branch, National Human Genome Research Institute, NIH, Bethesda, MD 20892, USA Correspondence and requests for materials should be addressed to X.J. (email: xjiang@coh.org) or to J.C. (email: jianchen@coh.org)